This contract expires in 176 days (Dec 31, 2026).
AURO VACCINES LLC - ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Key Details
Description
ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Context & Analysis
On Dec 1, 2025, Department of Health and Human Services obligated $10,728,082.6 to AURO VACCINES LLC for advanced development of multivalent vaccine candidates for filovirus and lassa fever. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 5 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in BALTIMORE, MD. The contract is scheduled through Dec 31, 2026 — approximately 6 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.